Clinical trials: Endocrine System Diseases
Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Ovarian Carcinoma
Irinotecan Liposome and Bevacizumab for the Treatment of Platinum Resistant, Recurrent, or Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
This phase II trial investigates the effect of irinotecan liposome and bevacizumab in treating patients with ovarian, fallopian tube, or primary peritoneal cancer that shows less response to platinum therapy (platinum resistant)…
- Conditions
- Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Ovarian Carcinoma, Platinum-Resistant Primary Peritoneal Carcinoma, Recurrent Fallopian Tube Carcinoma
- Trial name
- NCT04753216
- Testing
- Bevacizumab, Irinotecan Sucrosofate
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Northwestern University
Small Cell Lung Carcinoma, Non Small Cell Lung Carcinoma
Study of Carfilzomib With Irinotecan in Irinotecan-Sensitive Malignancies and Small Cell Lung Cancer Patients
The purpose of this study is to determine a well-tolerated dose of Carfilzomib in combination with Irinotecan (Phase 1b portion of the study) in subjects with relapsed small and non-small cell lung cancer or other…
- Conditions
- Small Cell Lung Carcinoma, Non Small Cell Lung Carcinoma, Irinotecan Sensitive Cancers
- Trial name
- NCT01941316
- Testing
- Carfilzomib, Irinotecan
- Where
- 8 sites in United States
- Volunteers
- 78 people
- Sponsor
- Cancer Research and Biostatistics Clinical Trials Consortium
Renal Insufficiency, Chronic, Hypertension
Supporting Self-Management of Healthy Behaviors in Diabetes, Kidney Disease, and Hypertension
The planned intervention, entitled, Supporting Self-Management of Health Behaviors to Optimize Health (SMART-HABITS for Health), aims to provide support for patients with chronic kidney disease (CKD), hypertension and diabetes by…
- Conditions
- Renal Insufficiency, Chronic, Hypertension, Diabetes
- Trial name
- NCT05565716
- Testing
- Support Person, Social Norms
- Where
- United States
- Volunteers
- 73 people
- Sponsor
- University of Pennsylvania
Diabetes Mellitus
Dario Blood Glucose Monitoring System - Android Devices Altitude Evaluation Study
This study evaluates the performance of a blood glucose monitoring system at high altitudes (approximately 10,000 feet). The performance is assessed via a reference method for glucose analysis (Yellow Springs Instrument 2300 STAT…
- Trial name
- NCT02916563
- Testing
- Blood Glucose Monitoring System Altitude Performance
- Where
- United States
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- LabStyle Innovations Ltd.
Diabetes Mellitus, Type 2
An Observational Study of Patient Cohorts Who Previously Received Long-term Treatment With Pioglitazone or Placebo in Addition to Existing Antidiabetic Medications
The purpose of this study was to investigate the mortality and macrovascular morbidity as well as the incidence of malignancies over time, in high-risk diabetic participants who previously received long-term treatment with either…
- Trial name
- NCT02678676
- Testing
- No Intervention
- Volunteers
- 3,599 people
- Sponsor
- Takeda
Diabetes Mellitus, Type 2
To Bathe or Not to Bathe
Type 2 diabetes mellitus (T2DM) is characterised by chronic high blood sugar concentration (hyperglycaemia) and insulin resistance leading to a reduction in insulin sensitivity.
- Trial name
- NCT03798717
- Testing
- Heating
- Where
- United Kingdom
- Volunteers
- 20 people
- Sponsor
- University of Portsmouth
Dwarfism, Pituitary
Predictive Markers in Chinese Growth Hormone Deficiency (GHD) Children Treated With Saizen®
This is an open-label, prospective, multicentric, non-comparative, non-randomized Phase IV interventional study in which subjects pre-diagnosed with Growth Hormone Deficiency (GHD) were treated for 4 weeks with Saizen to compare…
- Trial name
- NCT01187550
- Testing
- Recombinant human growth hormone (r-hGH)
- Volunteers
- 214 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
Pancreas Cancer, Pancreatic Cancer
Targeting Pancreatic Cancer With Sodium Glucose Transporter 2 (SGLT2) Inhibition
This is a first-in-human, pilot study of the feasibility and safety of dapagliflozin (in addition to standard of care treatment) for the treatment of patients with metastatic pancreatic ductal adenocarcinoma.
- Conditions
- Pancreas Cancer, Pancreatic Cancer, Cancer of the Pancreas
- Trial name
- NCT04542291
- Testing
- Dapagliflozin, BIOSENSE meters
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Washington University School of Medicine
Polycystic Ovary Syndrome
Treating Inflammation in Polycystic Ovary Syndrome to Ameliorate Ovarian Dysfunction
Polycystic Ovary Syndrome (PCOS) is characterized by hyperandrogenism, ovulatory dysfunction and polycystic ovaries. Insulin resistance (IR) is a common feature of PCOS, and the resultant hyperinsulinemia is theorized to promote…
- Trial name
- TIN-PCOS-AOD (NCT03229408)
- Testing
- Salsalate
- Where
- United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- University of Illinois Chicago
Gestational Diabetes
RCT Metformin for Reduction of Gestational Diabetes Mellitus Effects
The overall objective of the EMERGE trial is to determine whether metformin + usual care, compared to placebo + usual care (introduced at the time of initial diagnosis of GDM), reduces a) the need for insulin use, or…
- Trial name
- EMERGE (NCT02980276)
- Testing
- Metformin Hydrochloride
- Where
- 2 sites in Ireland
- Volunteers
- 535 people
- Sponsor
- National University of Ireland, Galway, Ireland
Diabetes Mellitus Type 2
GLP-1 Receptor Agonist Lixisenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Pioglitazone
The purpose of this study is to evaluate the benefits and risks of lixisenatide (AVE0010), in comparison to placebo, as an add-on treatment to pioglitazone with or without metformin, over a period of 24 weeks of treatment…
- Trial name
- GETGOAL-P (NCT00763815)
- Testing
- Lixisenatide (AVE0010), Pen auto-injector, Pioglitazone
- Where
- 150 sites in United States, Austria and 11 more
- Volunteers
- 484 people
- Sponsor
- Sanofi
Insular Thyroid Cancer, Recurrent Thyroid Cancer
Suberoylanilide Hydroxamic Acid in Treating Patients With Metastatic and/or Locally Advanced or Locally Recurrent Thyroid Cancer
This phase II trial is studying how well suberoylanilide hydroxamic acid works in treating patients with metastatic and/or locally advanced or locally recurrent thyroid cancer.
- Conditions
- Insular Thyroid Cancer, Recurrent Thyroid Cancer, Stage II Follicular Thyroid Cancer, Stage II Papillary Thyroid Cancer
- Trial name
- NCT00134043
- Testing
- vorinostat
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- National Cancer Institute (NCI)
Ovarian Sarcoma, Recurrent Fallopian Tube Carcinoma
A Phase II Study of Akt Inhibitor MK2206 in the Treatment of Recurrent Platinum-Resistant Ovarian, Fallopian Tube, or Peritoneal Cancer
Akt inhibitor MK2206 is a drug that may stop cancer cells from growing by blocking a protein called protein kinase B (AKT) inside the cell.
- Conditions
- Ovarian Sarcoma, Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma
- Trial name
- NCT01283035
- Testing
- Akt Inhibitor MK2206, Laboratory Biomarker Analysis
- Where
- 6 sites in United States
- Volunteers
- 6 people
- Sponsor
- National Cancer Institute (NCI)
Type 2 Diabetes
Safety and Feasibility of a Novel Endoscopic Intervention for the Treatment of Type II Diabetes
This is an open-label study to assess the safety and feasibility of the DyaMX device for endoscopic duodenal mucosal regeneration in individuals with type 2 diabetes inadequately controlled on glucose-lowering medications.
- Trial name
- REGENT-1 (NCT04725890)
- Testing
- The DyaMX Device
- Where
- 2 sites in Australia
- Volunteers
- 65 people
- Sponsor
- Endogenex, Inc.
Hypercortisolism
A Study of the Efficacy and Safety of Relacorilant in Patients With Cortisol-Secreting Adrenal Adenomas
This is a Phase 3, randomized, double-blind, placebo-controlled study to assess the efficacy, and safety of relacorilant to treat hypercortisolism in patients with cortisol-secreting adrenal adenoma or hyperplasia associated with…
- Trial name
- GRADIENT (NCT04308590)
- Testing
- Relacorilant
- Where
- 45 sites in United States, Austria and 7 more
- Volunteers
- 137 people
- Sponsor
- Corcept Therapeutics
Human Immunodeficiency Virus Infection, Sexually Transmitted Diseases
Men Together Making a Difference: Reducing HIV/STD Risk Behavior Among South African Men
Sub-Saharan Africa has about 10% of the world's population, but was home to more than 60% of all people living with HIV in 2003.
- Trial name
- NCT01490359
- Testing
- Men Making a Difference HIV/STD Risk Reduction Intervention, Health Promotion Control
- Volunteers
- 1,181 people, healthy volunteers welcome
- Sponsor
- University of Pennsylvania
Ovarian Cancer
Fulvestrant in Treating Patients With Recurrent Ovarian Epithelial Cancer
RATIONALE: Estrogen can cause the growth of ovarian epithelial cancer cells. Hormone therapy using fulvestrant may fight ovarian cancer by blocking the use of estrogen by the tumor cells.
- Trial name
- NCT00617188
- Testing
- Fulvestrant
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- Masonic Cancer Center, University of Minnesota
Diabetic Foot Ulcer
Preventing Diabetic Foot Ulcers Through Cleaner Feet
Foot complications are among the most serious and costly complications of diabetes. People with diabetes have a 10-fold increased risk for a leg or foot amputation compared to those that do not have diabetes.
- Trial name
- NCT03503370
- Testing
- Chlorhexidine
- Where
- United States
- Volunteers
- 175 people
- Sponsor
- VA Office of Research and Development
Short Stature
IGF-1 Treatment for Individuals With Short Stature Due to PAPP-A2 Deficiency
With this study we want to investigate the pharmacokinetic (PK) effect of a single injection of rhIGF-1 in patients with PAPP-A2 mutations compared to heterozygous carriers and healthy controls.
- Trial name
- NCT02636270
- Testing
- Increlex
- Volunteers
- 7 people, healthy volunteers welcome
- Sponsor
- Children's Hospital Medical Center, Cincinnati
Pancreatic Cancer
QUILT-3.070:Pancreatic Cancer Vaccine: Subjects With Pancreatic Cancer Who Have Progressed on or After Standard-of-care Therapy
This is a phase 1b/2 study to evaluate the safety and efficacy of metronomic combination therapy in subjects with pancreatic cancer who have progressed on or after previous SoC chemotherapy.
- Trial name
- NCT03387098
- Testing
- Aldoxorubicin HCl, ALT-803, ETBX-011
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- ImmunityBio, Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.